Janus Henderson Group plc filed an amendment to a Schedule 13G reporting beneficial ownership of 13,179,013 shares of BridgeBio Pharma, Inc. Common Stock, representing 6.8% of the class as shown with a 03/31/2026 date line. The filing states the Asset Managers exercise shared voting and dispositive power over these shares (each listed with 13,179,013 votes/ dispositive power) and includes a disclaimer that the Asset Managers do not have rights to dividends or sale proceeds for the managed accounts. The filing was signed by Kristin Mariani as Head of North America Compliance on 5/15/2026 and references Exhibit 99 for Item 7 details.
Positive
None.
Negative
None.
Insights
Large passive position reported by Janus Henderson owning 13,179,013 shares (6.8%).
The amendment clarifies that multiple Janus Henderson Asset Managers exercise shared voting and shared dispositive power over 13,179,013 shares of BridgeBio Pharma as of 03/31/2026. The filing frames ownership as held in managed client accounts rather than proprietary holdings.
Key dependencies include the composition of the Managed Portfolios and any subsequent Schedule 13D/13G amendments; future filings would reflect changes in voting or dispositive power.
Amendment positions are procedural and disclose voting/dispositive arrangements and a dividend/proceeds disclaimer.
The report lists the parent Janus Henderson Group plc and enumerates multiple SEC-registered advisers managing client accounts that may be deemed beneficial owners by virtue of investment discretion. It emphasizes that the Asset Managers disclaim rights to dividends and sale proceeds tied to those accounts.
Material follow-ups would be further amendments if voting authority or percent ownership crosses regulatory thresholds; filings reference Exhibit 99 for subsidiary classification per Item 7.
Key Figures
Reported shares beneficially owned:13,179,013 sharesPercent of class:6.8%Voting/Dispositive power (shared):13,179,013 shares
3 metrics
Reported shares beneficially owned13,179,013 sharesListed in Item 4 of the Schedule 13G/A
Percent of class6.8%Percent of common stock stated in Item 4
Voting/Dispositive power (shared)13,179,013 sharesShared power to vote and dispose per Item 4
Key Terms
Beneficial owner, Managed Portfolios, Shared dispositive power
3 terms
Beneficial ownerregulatory
"‘‘may be deemed to be the beneficial owner of 13,179,013 common stock’’"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Managed Portfoliosfinancial
"‘‘clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios)’’"
Shared dispositive powerregulatory
"‘‘Shared power to dispose or to direct the disposition of: 13179013’’"
What stake does Janus Henderson Group plc report in BBIO?
Janus Henderson Group plc reports beneficial ownership of 13,179,013 shares, representing 6.8% of BridgeBio Pharma's common stock as indicated in the amendment. The position is attributed to its Asset Managers exercising investment discretion on behalf of managed client accounts.
Does Janus Henderson have sole voting or dispositive power over these BBIO shares?
No. The amendment states 0 shares with sole voting or dispositive power and 13,179,013 shares with shared voting and shared dispositive power, indicating joint authority among the listed Asset Managers.
Are the shares held directly by Janus Henderson or by client accounts?
The filing explains the shares are held in multiple Managed Portfolios for clients and that Asset Managers exercise voting/dispositive discretion on their behalf; the Asset Managers disclaim rights to dividends or sale proceeds tied to those managed accounts.
What exhibits accompany the Schedule 13G/A amendment?
The amendment references Exhibit 24 (Power of Attorney) and Exhibit 99 (Item 7 subsidiary identification/classification). Exhibit 99 is noted for identifying the relevant subsidiary or classification information required under Item 7.
When was the amendment signed and filed for BBIO ownership disclosure?
The amendment bears a signature by Kristin Mariani, Head of North America Compliance, dated 5/15/2026, and the cover shows an internal date line of 03/31/2026 associated with the reported holdings in the filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
BRIDGEBIO PHARMA, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
10806X102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
10806X102
1
Names of Reporting Persons
JANUS HENDERSON GROUP PLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
13,179,013.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
13,179,013.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
13,179,013.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.8 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BRIDGEBIO PHARMA, INC.
(b)
Address of issuer's principal executive offices:
3160 PORTER DR., SUITE 250
PALO ALTO, CA 94304
Item 2.
(a)
Name of person filing:
Janus Henderson Group plc
(b)
Address or principal business office or, if none, residence:
201 Bishopsgate
EC2M 3AE, United Kingdom
(c)
Citizenship:
Y9
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
10806X102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Janus Henderson Group plc (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, and Victory Park Capital Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 13,179,013 common stock of Bridgebio Pharma, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)
Percent of class:
6.8 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
13179013
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
13179013
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.
Of the Managed Portfolios, none own more than five percent of the common stock of Bridgebio Pharma, Inc.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please refer to Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
